Strathcona Resources (OTCPK:STHRF) said Friday it formally launched its offer to acquire MEG Energy (OTCPK:MEGEF) that values ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Income investing isn’t meant to create fabulous wealth in a month or even a year. After a quarter-century of successful ...

Bone and muscle health is key to prevent the risk of falling and fractures which can lead to premature death or else have a ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

There have been important recent advances in the management of Crohn's disease, including new classes of biological or small molecule therapies, an appreciation that endoscopic mucosal healing results ...